Combined senolytic immunotherapy (SenoVax) with pluripotent stem cell-derived mesenchymal stem cells dramatically outperformed either treatment alone in reversing aging markers and liver damage in mice. The combination restored regenerative biomarkers like Klotho and GDF-11 while suppressing inflammatory SASP factors including IL-11 and IL-6. Critically, stem cells showed minimal benefit when senescent cell burden remained high, but became highly effective after senescent cell clearance. This validates a key mechanistic insight: senescent cells actively sabotage regenerative therapies through SASP factor secretion. The finding represents a potential paradigm shift from sequential to simultaneous anti-aging interventions. While promising, several limitations temper enthusiasm. The study used accelerated aging models rather than natural aging, and mouse physiology may not translate directly to humans. The proprietary SenoVax immunotherapy lacks published safety data, and the pluripotent stem cell source raises regulatory hurdles. Most significantly, no actual lifespan data was provided despite the title's bold claim. Still, the mechanistic clarity around SASP interference with regeneration offers a compelling rationale for combination approaches in aging research and could inform clinical trial design.